StreetAlpha.app
Home › Stocks › IGC

IGC Pharma, Inc. (IGC)

$0.18
▲ +3.08%
LAST CLOSE · NOV 17

IGC Pharma develops drug candidates for Alzheimer's disease, with its lead candidate in clinical trials for agitation linked to the condition. It last closed at $0.18 on Nov 17, up 3.08% on the day. IGC last reported earnings on Thu, Aug 13, 2026.

AI Auto Pilots
Is IGC in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$1.3M
+13.9% vs a year ago
Net income
−$8.1M
−643.7% margin
EPS (diluted)
−$0.08
Free cash flow
−$5.2M
−415.2% margin
Valuation
Market cap
$21.5M
116.7M shares
P/E
–
No P/E while losing money
Price to sales
17.0
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$377K
At Sep 30
Debt
$128K
At Sep 30
Shareholder equity
$6.5M
Shares outstanding
116.7M
At Nov 3
Fiscal year endsDecember
ExchangeNYSE
Financials history
FY2021: $898K$898KFY2021FY2022: $397K$397KFY2022FY2023: $911K$911KFY2023FY2024: $1.3M$1.3MFY2024FY2025: $1.3M$1.3MFY2025

From IGC's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 6). Last 12 months adds up the four latest quarters.

Last report
Aug 13
2026 · Time not announced
Reported EPS
-$0.03
vs -$0.02 est. · miss
Year-ago EPS
-$0.01
Same quarter last year
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated IGC in the past 90 days, not enough for a consensus
Average 12-month target
$6.00
▲ 3160.9% upside

Based on 1 analyst who set a price target on IGC in the past 90 days. The average target is $6.00, with a high of $6.00 and a low of $6.00, compared with the last close of $0.18.

Low $6.00Avg $6.00High $6.00
Blue marker: last close $0.18
Highest target$6.00
Average target$6.00
Lowest target$6.00
Latest rating changes
Ascendiant CapitalTarget raised
Aug 26Buy$5.50 → $6
Ascendiant CapitalMaintained
Jun 8Buy$5.50
DateFirmActionRatingPrice target
Aug 26Ascendiant CapitalTarget raisedBuy$5.50 → $6
Jun 8Ascendiant CapitalMaintainedBuy$5.50
Loading…

Technical Analysis

IGC · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 12% below its 20 day and 34% below its 50 day average. It is 49% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 34), near oversold. The nearest support is the Pivot at $0.18, and the nearest resistance the Pivot R1 at $0.19.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 9.6%/day
Key levels
$0.3752 week high+105.6%
$0.27200 day average+50.0%
$0.26100 day average+44.4%
$0.2550 day average+38.9%
$0.2120 day average+16.7%
$0.21Swing high (Nov 9)+16.7%
$0.19Pivot R1+5.6%
$0.18Pivot+0.0%
$0.18Pivot S1+0.0%
$0.18Swing low (Nov 5)+0.0%
$0.18Last close
$0.0852 week low−55.6%
Indicators
RSI (14)33.57Weak, oversold below 30Neutral
MACD-0.02Below its signal lineBearish
Stochastic58.8Middle of its rangeNeutral
ADX (14)58.8Strong downtrend
Williams %R-37.0Oversold below −80, overbought above −20Neutral
CCI (20)-62.4Oversold below −100, overbought above 100Neutral
Rate of change−3.7%Change over 10 sessionsBearish
ATR (14)$0.02Typical daily range, 9.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IGC

What happened before

See how IGC did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IGC usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IGC has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IGC in the last 90 days.

Loading…

See today’s whale options flow across the market →

IGC Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▼11 buying vs 15 selling
  • ▲Held by funds +0.9 pts
  • ▼Funds holding -7
  • ▲Superinvestors: 2 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding2936−19.4%
In funds' top 1000–
Held by funds5.4%4.5%+0.9 pts
New / increased2 / 96 / 7−15.4%
Reduced / sold out6 / 97 / 4+36.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IGC institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IGC is in one of them and how their past IGC trades turned out.

IGC in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IGC in an article yet. Here's the latest on the wider market.

About IGC Pharma

IGC Pharma is a drug development company based in Potomac, Maryland, focused mainly on Alzheimer's disease. Its lead candidate, IGC-AD1, is in a clinical trial for agitation, a behavioral symptom common in people with Alzheimer's dementia. The company is also building MINT-AD, an artificial intelligence data tool meant to support clinicians and researchers in assessing risk in Alzheimer's patients. It does not yet sell pharmaceutical products.

Headquarters
Potomac, MD